Fresolimumab

From Wikipedia, the free encyclopedia
Fresolimumab ?
Monoclonal antibody
Type Whole antibody
Source Human
Target TGF beta 1, 2 and 3
Clinical data
Legal status Investigational
Identifiers
CAS number 948564-73-6 N
ATC code None
KEGG D09620 YesY
Chemical data
Formula C6392H9926N1698O2026S44 
Mol. mass 144.4 kDa
 N (what is this?)  (verify)

Fresolimumab (GC1008) is a human monoclonal antibody[1] and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer[2][3] (kidney cancer and melanoma).

It binds to and inhibits all isoforms of the protein transforming growth factor beta (TGF-β).[2]

History

Fresolimumab was discovered by Cambridge Antibody Technology (CAT) and was one of a pair of candidate drugs that were identified for the treatment of the fatal condition scleroderma. CAT chose to co-develop the two drugs metelimumab (CAT-192) and fresolimumab with Genzyme. During early development, around 2004, CAT decided to drop development of metelimumab in favour of fresolimumab.[4]

In February 2011 Sanofi-Aventis agreed to buy Genzyme for US$ 20.1 billion.[5]

As of June 2011 the drug was being tested in humans (clinical trials) against IPF, renal disease, and cancer.[6][7] On 13 August 2012, Genzyme applied to begin a Phase 2 clinical trial in primary focal segmental glomerulosclerosis[8] comparing fresolimumab versus placebo.

As of March 2013, Sanofi-Aventis continue to list fresolimumab in their research and development portfolio.[9]

References


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.